GSK 649868
Alternative Names: GSK649868; GW649868; orexin-antagonist; SB-649868Latest Information Update: 05 Nov 2023
At a glance
- Originator GlaxoSmithKline; Human Genome Sciences
- Developer GlaxoSmithKline
- Class Amides; Piperidines; Sleep disorder therapies; Small molecules
- Mechanism of Action Orexin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sleep disorders
Most Recent Events
- 03 Aug 2012 GlaxoSmithKline acquires Human Genome Sciences
- 20 Aug 2009 Pharmacokinetics and pharmacodynamics data from animal studies in sleep disorders presented at the 238th American Chemical Society National Meeting (238th-ACS-2009)
- 31 Jan 2007 Phase-I clinical trials in Sleep disorders in United Kingdom (PO)